Issues
Cancer Research
Table of Contents
Perspectives in Cancer Research
Advances in Brief
Absence of Genetic Alteration at Codon 531 of the Human c-src Gene in 479 Advanced Colorectal Cancers from Japanese and Caucasian Patients1
Distinct Expression Patterns of the p53-Homologue p73 in Malignant and Normal Hematopoiesis Assessed by a Novel Real-Time Reverse Transcription-Polymerase Chain Reaction Assay and Protein Analysis1
Biochemistry
Carcinogenesis
Clinical Investigations
High Telomerase Reverse Transcriptase (hTERT) Messenger RNA Level Correlates with Tumor Recurrence in Patients with Favorable Histology Wilms’ Tumor1
Endocrinology
Epidemiology and Prevention
Experimental Therapeutics
p53 Selective and Nonselective Replication of an E1B-deleted Adenovirus in Hepatocellular Carcinoma1
Decrease in Susceptibility Toward Induction of Apoptosis and Alteration in G1 Checkpoint Function as Determinants of Resistance of Human Lung Cancer Cells against the Antisignaling Drug UCN-01 (7-Hydroxystaurosporine)
Tumor Biology
Protein Kinase C Lies on the Signaling Pathway for Vascular Endothelial Growth Factor-mediated Tumor Development and Angiogenesis
CD44 Stimulation Induces Integrin-mediated Adhesion of Colon Cancer Cell Lines to Endothelial Cells by Up-Regulation of Integrins and c-Met and Activation of Integrins1
Letters to the Editor
Errata
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds